Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences

Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech firm, announced its participation in several upcoming conferences aimed at improving prescription drug safety. Key events include the PAINWeek Conference from September 6-9, 2022, where CEO Dr. Lynn Kirkpatrick will chair a symposium, and the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The meetings will provide opportunities for one-on-one discussions with company executives regarding their transformative technologies for pain management.

SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced its participation in the following upcoming conferences:

• PAINWeek Conference 2022, September 6 - September 9, 2022, in Las Vegas, NV. Dr. Lynn Kirkpatrick, Chief Executive Officer, to chair a symposium and panel, entitled, "Severe Pain, Strategic Perspectives." The symposium will be held on September 9^th from 12:30 p.m. - 1:30 p.m. Pacific time.
• H.C. Wainwright 24^th Annual Global Investment Conference, September 12 - September 14, 2022, at the Lotte New York Palace Hotel, New York, NY.
• Lake Street 6^th Annual Best Ideas Growth Conference, Wednesday, September 14, 2022, at The Yale Club, New York, NY.
• New Product Planning Summit, September 19-20, 2022, in Boston, MA. Geoff Birkett, Chief Commercial Officer, to chair the meeting and speak on his prior experience launching several major neuroscience and pain products.

The Company's Chief Executive Officer, Dr. Lynn Kirkpatrick, and Chief Financial Officer, Dave Humphrey, will be available for one-on-one meetings during both the H.C. Wainwright and Lake Street conferences. For more information about the events or to schedule a one-on-one meeting with Ensysce's management, please contact Ensysce's Investor Relations at ENSC@mzgroup.us.

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse, reducing the human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.

Ensysce Biosciences Company Contact
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:
MZ Group North America
Shannon Devine
203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/713235/Ensysce-Biosciences-Inc-Announces-Participation-in-Upcoming-Conferences

FAQ

What conferences will Ensysce Biosciences participate in September 2022?

Ensysce Biosciences will participate in the PAINWeek Conference, H.C. Wainwright 24th Annual Global Investment Conference, Lake Street 6th Annual Best Ideas Growth Conference, and New Product Planning Summit.

Who is leading the symposium at the PAINWeek Conference?

Dr. Lynn Kirkpatrick, the CEO of Ensysce Biosciences, will lead the symposium titled 'Severe Pain, Strategic Perspectives' on September 9, 2022.

Where is the H.C. Wainwright 24th Annual Global Investment Conference held?

The H.C. Wainwright 24th Annual Global Investment Conference is taking place at the Lotte New York Palace Hotel in New York, NY, from September 12 to 14, 2022.

What technology does Ensysce Biosciences focus on for drug safety?

Ensysce is focused on its Trypsin Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR™) platforms to develop safer prescription drugs.

How can investors schedule a meeting with Ensysce's management?

Investors can schedule one-on-one meetings with Ensysce's management during the H.C. Wainwright and Lake Street conferences by contacting their Investor Relations at enscc@mzgroup.us.